Background and Purpose: Drug addiction is a complex disease specified by exacerbation and repetition, uncontrollable penchant, with involuntary seeking for drugs and continuous consumption of that, with its horrible and destructive results. According to the problems which we would be faced with them during drug addiction treatment, this article is going to study on these problems. method: For this study the theoretical foundations and retaining
the existing research literature on the subject was discussed. Results: In this paper, the problems related with addiction treatment, the history of drug addiction treatment, the role of opioid preservative (Methadone and Buprenorphine) and its advantages (such as reducing criminal activities, increasing productivity, improving physical functions, Social and mental health, and limiting the blood-borne pathogens) and the weakness (such as the common side effects of constipation, dizziness, dry mouth, headache, increased transpiration, itching, nausea, sleep problems, and psychiatric disorders) are presented.Conclusion: Although long-term and even short-term addiction prevention and treatment programs will be effective, but the large population of domestic drug users remains a major concern for researchers, their families, therapists, and legal responses. An effective treatment process is one of the major challenges of contemporary research and clinical practice that should help clients to defense with destructive effects of brain addiction and behavior, and regaining control of life and restoring clients to productive functions in the family, workplace and community. addiction treatment using chemical drugs is one of the most difficult, most dangerous, and most responsible drug treatments, and the doctors should also be fully trained in the correct administration of agonist medications, and they must be so patient and educated to their patients.
Key words: Addiction, Pharmacotherapy, Conservative treatment, Treatment problems, The effectiveness of treatment, relapse, prevention
Evaluation of postpartum depression and relationship its with spiritual healt...
Problems and Issues Facing Pharmacotherapy of Addiction
1. www.PSYCHOconf.ir1
Problems and Issues Facing Pharmacotherapy of Addiction
SG. Seyed Hashemi1
, F. Haghighati2
, H. Kord3
1- MSc in Psychology, Faculty of Psychology and Educational Sciences, Azarbaijan Shahid Madani
University, Tabriz, Iran (Corresponding Author): Tel: 09147270904, E-Mail:
seyedhashemi@azaruniv.ac.ir
2 & 3- MSc in Psychology, Faculty of Psychology and Educational Sciences, Azarbaijan Shahid
Madani University, Tabriz, Iran
Abstract
Background and Purpose: Drug addiction is a complex disease specified
by exacerbation and repetition, uncontrollable penchant, with involuntary
seeking for drugs and continuous consumption of that, with its horrible and
destructive results. According to the problems which we would be faced
with them during drug addiction treatment, this article is going to study on
these problems. method: For this study the theoretical foundations and
retaining the existing research literature on the subject was discussed.
Results: In this paper, the problems related with addiction treatment, the
history of drug addiction treatment, the role of opioid preservative
(Methadone and Buprenorphine) and its advantages (such as reducing
criminal activities, increasing productivity, improving physical functions,
Social and mental health, and limiting the blood-borne pathogens) and the
weakness (such as the common side effects of constipation, dizziness, dry
mouth, headache, increased transpiration, itching, nausea, sleep problems,
and psychiatric disorders) are presented. Conclusion: Although long-term
and even short-term addiction prevention and treatment programs will be
effective, but the large population of domestic drug users remains a major
concern for researchers, their families, therapists, and legal responses. An
effective treatment process is one of the major challenges of contemporary
research and clinical practice that should help clients to defense with
destructive effects of brain addiction and behavior, and regaining control of
life and restoring clients to productive functions in the family, workplace
and community. addiction treatment using chemical drugs is one of the most
difficult, most dangerous, and most responsible drug treatments, and the
doctors should also be fully trained in the correct administration of agonist
medications, and they must be so patient and educated to their patients.
Keywords: Addiction, Pharmacotherapy, Conservative treatment,
Treatment problems, The effectiveness of treatment, relapse, prevention
10. www.PSYCHOconf.ir10
خطرن ،ها آن از مواد ی کننده مصرف سوء بیمارواسطه به بیماران از دسته این دیگر سوی از .است کشنده حتی و اک
نحوه و دارو از مراقبت در ،بیماری این های ویژگیپیامدهای رخداد احتمال و ندارند کافی دقت آن مصرف صحیح ی
است مواد مصرف سوء و درمان مراکز مدیریتی و پزشکی های دغدغه ترین مهم از دیگر یکی قانونی و پزشکینیز پزشکان .
بیماران به حوصله با و بیاموزند کامل طور به را آگونیستی داروهای تجویز صحیح ی نحوه زمینه در الزم های آموزش باید
سطح سو یک از که باید نیز اعتیاد پذیری بازگشت ویژگی با رابطه در .دهند قرار پایش مورد را آن و داده آموزش خود
واق به را ها خانواده توقع،غیردارویی و دارویی ای چندجانبه های درمان ی ارایه با دیگر سوی از و کند نزدیک موجود عیت
ارائه و پایین دوزهای تجویز با افیونی غیر های دارو به وابستگی از امکان حد تا و .برسانند حداقل به را بازگشت امکان
[کنند پیشگیری غیردارویی راهکارهای81-82.]
References
1.Naderi, N., Binazadeh, M., Sefatian, S., & Asghar Peyvandi, A. (2009). Comprehensive
text book of addiction: Dependence to different substances and their pharmacological and
non-pharmacological treatment. Tehran, Iran: Drug Control Headquarters.
2.Flura K & Stalikas A (2013) Factors affecting substance abuse treatment across different
treatment phases. International Journal of Psychosocial Rehabilitation, 17(1), 89-104.
3.West, R., Hardy, A. (2005) Theory of addiction. Oxford. Blackwell Publishing Ltd.
4. Mokri, A. (2002). Brief overview of the status of drug abuse in Iran. Archives of Iranian
Medicine, 5(3), 184-90.
5. De Kort, G., Vazirian, M., & Nassirimanesh, B. (2006). Young people and drugs–
Towards a comprehensive health promotion policy–Tehran report. Asian Harm Reduction
Network (AHRN) Final Report.
6.World Health Organization. (2009). Guidelines for the psychosocially assisted
pharmacological treatment of opioid dependence. Geneva, Switzerland: Author.
7. Stein, D., Lerer, B., & Stahl, S. M. (Eds.). (2012). Essential evidence-based
psychopharmacology (2nd ed.). Cambridge; New York: Cambridge University Press.
8. Flora, K., & Stalikas, A. (2013) Factors affecting substance abuse treatment across
different treatment phases. International Journal of Psychosocial Rehabilitation, 17(1), 89-
104.
9.DiClemente, C.C. & Scott, C.W. (1997). Stages of change: interaction with treatment
compliance and involvement. In L.S. Onken, J.D. Blaine, & J.J.Boren, (eds.), Beyond the
Therapeutic Alliance: Keeping the Drug-Dependent Individual in Treatment. Rockville,
MD: National Institute on Drug Abuse.
10. Long, C. G., Hollin, C. R., & Williams, M. J. (1998). Self-efficacy, outcome
expectations, and fantasies as predictors of alcoholics' posttreatment drinking. Substance
use & misuse, 33(12), 2383-2402.
11.Izquierdo, F. M., de Osma, F. J., Arnedillo, J. J., Cotaberria, A.M. (2001). Self-concept,
self-esteem, locus of control and self-efficacy in alcohol dependence. [Spanish]. Anales de
Psiquiatria, 17(4),153-161.
11. www.PSYCHOconf.ir11
12.Burleson, J.A., Kaminer, Y., (2005). Self-efficacy as a predictor of treatment outcome
in adolescent substance use disorders. Addictive Behaviors, 30(9), 1751-1764.
13.Ilgen, M., McKellar, J., & Moos, R. (2007). Personal and treatment-related predictors of
abstinence self-efficacy. Journal of Studies on Alcohol and Drugs, 68(1), 126-132.
14. Solomon, K. E., & Annis, H. M. (1990). Outcome and efficacy expectancy in the
prediction of post‐treatment drinking behaviour. Addiction, 85(5), 659-665.
15.Colon, I. & Massey, R.K. (1988). Patient attitudes and beliefs as predictors of treatment
outcome in detoxification: A pilot study. Alcoholism Treatment Quarterly, 5(3-4), 235-
244.
16.Dearing, R.L., Barrick, C., Dermen, K.H. & Walitzer, K. S. (2005). Indicators of Client
Engagement: Influences on Alcohol Treatment Satisfaction and Outcomes. Psychology of
Addictive Behaviors, 19(1), 71-78.
17.Joe, G.W., Flynn, P.M., Broome, K.M. & Simpson, D.D. (2007). Pattern of drug use
and expectations in methadone patients. Addictive behaviours, 32(8), 1640-1656.
18.Joyce, Α.S. & Pipper, W.E. (1998). Expectancy, the therapeutic alliance, and treatment
outcome in short-term individual psychotherapy. Journal of Psychotherapy Practice &
Research. 7(3), 236-248.
19. Kreek, M. J. (2000). Methadone‐Related Opioid Agonist Pharmacotherapy for Heroin
Addiction: History, Recent Molecular and Neurochemical Research and Future in
Mainstream Medicine. Annals of the New York Academy of Sciences, 909(1), 186-216.
20. US Department of Health and Human Services. (2002). Substance Abuse and Mental
Health Services Administration. (2003). A national call to action: Eliminating the use of
seclusion and restraint.
21. Soyka, M., Kranzler, H. R., Berglund, M., Gorelick, D., Hesselbrock, V., Johnson, B.
A., ... & Berglund, M. (2008). World Federation of Societies of Biological Psychiatry
(WFSBP) guidelines for biological treatment of substance use and related disorders, part 1:
alcoholism. The World Journal of Biological Psychiatry, 9(1), 6-23.
22. Soyka, M., Kranzler, H. R., van den Brink, W., Krystal, J., Möller, H. J., & Kasper, S.
(2011). The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines
for the biological treatment of substance use and related disorders. Part 2: Opioid
dependence. The world journal of biological psychiatry, 12(3), 160-187.
23. Snyder, J. L., & Bowers, T. G. (2008). The efficacy of acamprosate and naltrexone in
the treatment of alcohol dependence: a relative benefits analysis of randomized controlled
trials. The American journal of drug and alcohol abuse, 34(4), 449-461.
24. Streeton, C., & Whelan, G. (2001). Naltrexone, a relapse prevention maintenance
treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol
and Alcoholism, 36(6), 544-552.
25. Boothby, L. A., & Doering, P. L. (2005). Acamprosate for the treatment of alcohol
dependence. Clinical therapeutics, 27(6), 695-714.
12. www.PSYCHOconf.ir12
26.Mattick, R., Kimber, J., Breen, C., Davoli, M. (2008) Buprenorphine maintenance
versus placebo or methadone maintenance for opioid dependence. The Cochrane Database
of Systematic Reviews, 16 (2), CD002207.
27.Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance
therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database
of Systematic Reviews, 3, 1–31.
28.Barnett PG. (2009) Comparison of costs and utilization among buprenorphine and
methadone patients. Addiction, 104(6), 982–92.
29.Barnett PG, Zaric GS, Brandeau ML. (2001) The cost-effectiveness of buprenorphine
maintenance therapy for opiate addiction in the United States. Addiction, 96(9), 1267–78.
30.Connock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R. J., & Taylor,
R. S. (2007). Methadone and buprenorphine for the management of opioid dependence: A
systematic review and economic evaluation. Health Technology Assessment, 11, 1–171.
31.McLellan AT, McKay JR, Forman R, Cacciola J, Kemp J. (2005) Reconsidering the
evaluation of addiction treatment: from retrospective follow-up to concurrent recovery
monitoring. Addiction 100(4), 447-58.
32. Dole, V. P., & Nyswander, M. (1965). A medical treatment for diacetylmorphine
(heroin) addiction: a clinical trial with methadone hydrochloride. Jama, 193(8), 646-650.
33.Ward, J., W. Hall and R.P. Mattick. (1999) Role of maintenance treatment in opioid
dependence. Lancet, 353, 221–226.
34.Fareed, A., Casarella, J., Amar, R., Vayalapalli, S., & Drexler, K. (2010). Methadone
maintenance dosing guideline for opioid dependence—A literature review. Journal of
Addictive Diseases, 29(1), 1–14.
35.Marsch, L. A. (1998). The efficacy of methadone maintenance interventions in reducing
illicit opiate use, HIV risk behavior and criminality: A meta-analysis. Addiction, 93, 515–
532.
36.Bloor, M., J. McIntosh, N. McKeganey and M. Robertson. (2008) ‘Topping up’
methadone: an analysis of patterns of heroin use among a treatment sample of Scottish
drug users. Public Health, 122, 1013–1019.
37.Brady, T. M., Salvucci, S., Sverdlov, L. S., Male, A., Kyeyune, H., Sikali, E., et al.
(2005). Methadone dosage and retention: an examination of the 60 mg/day threshold.
Journal of Addictive Diseases, 24(3), 23–47.
38.Donny, E. C., Brasser, S. M., Bigelow, G. E., Stitzer, M. L., & Walsh, S. L. (2005).
Methadone doses of 100 mg or greater are more effective than lower doses at suppressing
heroin self-administration in opioid-dependent volunteers. Addiction, 100(10), 1496–1509.
39.Rounsaville, B. J., & Kleber, H. D. (1985). Untreated opiate addicts: how do they differ
from those seeking treatment?. Archives of General Psychiatry, 42(11), 1072-1077.
40.Gerstein, D. R., & Lewin, L. S. (1990). Treating drug problems. New England Journal
of Medicine, 323(12), 844-848.
41.Ward, J., W. Hall and R.P. Mattick. (1999) Role of maintenance treatment in opioid
dependence. Lancet, 353, 221–226.
13. www.PSYCHOconf.ir13
42.Stein, M. D., Herman, D. S., Bishop, S., Lassor, J. A., Weinstock, M., Anthony, J., &
Anderson, B. J. (2004). Sleep disturbances among methadone maintained patients. Journal
of substance abuse treatment, 26(3), 175-180.
43.Peles, E., S. Schreiber and M. Adelson. (2006) Variables associated with perceived
sleep disorders in methadone maintenance treatment (MMT) patients. Drug Alcohol
Depend. 82, 103–110.
44.Wang, W., Li, Q., Wang, Y., Tian, J., Yang, W., Li, W., ... & Liu, J. (2011). Brain
fMRI and craving response to heroin-related cues in patients on methadone maintenance
treatment. The American journal of drug and alcohol abuse, 37(2), 123-130.
45.Verdejo, A., Toribio, I., Orozco, C., Puente, K. L., & Pérez-García, M. (2005).
Neuropsychological functioning in methadone maintenance patients versus abstinent
heroin abusers. Drug and alcohol dependence, 78(3), 283-288.
46.Fudala, P. J., Bridge, T. P., Herbert, S., Chiang, C. N., & Leiderman, D. B. (1998). A
multisite efficacy evaluation of a buprenorphine/naloxone product for opiate dependence
treatment. NIDA Research Monograph, 179, 105.
47. Obadia, Y., Perrin, V., Feroni, I., Vlahov, D., & Moatti, J. P. (2001). Injecting misuse
of buprenorphine among French drug users. Addiction, 96(2), 267-272.
48.Walsh SL, Preston KL, Bigelow GE, Stitzer ML. (1995) Acute administration of
buprenorphine in humans: partial agonist and blockade effects. The Journal of
pharmacology and experimental therapeutics, 274(1), 361–72.
49.Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. (1994) Clinical
pharmacology of buprenorphine: ceiling effects at high doses. Clinical pharmacology and
therapeutics, 55(5), 569–80.
50.Kakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M. (2003). 1-year retention and
social function after buprenorphine-assisted relapse prevention treatment for heroin
dependence in Sweden: a randomised, placebo-controlled trial. The Lancet, 361(9358),
662-668.
51.Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., ... &
Ling, W. (2003). Office-based treatment of opiate addiction with a sublingual-tablet
formulation of buprenorphine and naloxone. New England Journal of Medicine, 349(10),
949-958.
52.Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. (1995) A
placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence.
Drug and alcohol dependence, 40(1), 17–25.
53. Long, C. G., Hollin, C. R., & Williams, M. J. (1998). Self-efficacy, outcome
expectations, and fantasies as predictors of alcoholics' posttreatment drinking. Substance
use & misuse, 33(12), 2383-2402.
54. Kosten, T. R., Schottenfeld, R., Ziedonis, D., & Falcioni, J. (1993). Buprenorphine
versus methadone maintenance for opioid dependence. The Journal of nervous and mental
disease, 181(6), 358-364.
55.،اسدافروزتقی محمد(1387شیراز .مخدر وترکمواد اعتیاد یابی ریشه .):.مهر کوشاه انتشارات
14. www.PSYCHOconf.ir14
56.McLellan AT, McKay JR, Forman R, Cacciola J, Kemp J. (2005) Reconsidering the
evaluation of addiction treatment: from retrospective follow-up to concurrent recovery
monitoring. Addiction 100(4),447-58.
57.Emrick, C. D. (1975). A review of psychologically oriented treatments for alcoholism
II. The relative effectiveness of different treatment approaches and the effectiveness of
treatment versus no treatment. Journal of Studies on Alcohol, 36, 88–108.
58.Armor, D. J., Polich, J. M. & Stambul, H. B. (1976). Alcoholism and Treatment. Santa
Monica, CA: RAND Corporation Press. In: Ball, J. C. & Ross, A. (1991) The Effectiveness
of Methadone Maintenance Treatment. New York: Springer-Verlag.
59. Hubbard, R. L., Marsden, M. E., Rachal, J. V., Harwood, H. J., Cavanaugh, E. R., &
Ginzburg, H. M. (1989). Drug abuse treatment: A national study of effectiveness.
University of North Carolina Press.
60. Gerstein, D. R., & Lewin, L. S. (1990). Treating drug problems. New England Journal
of Medicine, 323(12), 844-848.
61.Ball J. C. & Ross, A. (1991). The Effectiveness of Methadone Maintenance Treatment.
New York: Springer-Verlag.
62.McLellan, A. T., Grissom, G., Alterman, A. I., Brill, P. & O’Brien, C. P. (1993)
Substance abuse treatment in the private setting: are some programs more effective than
others? Journal of Substance Abuse Treatment, 10, 243–254.
63.Finney, J. W., Hahn, A. C. & Moos, R. H. (1996) The effectiveness of in-patient and
out-patient treatment for alcohol abuse: the need to focus on mediators and moderators of
setting effects. Addiction, 91, 1773–1796.
64.Simpson, D. D., Joe, G. W. & Brown, B. S. (1997) Treatment retention and follow-up
outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychology of
Addictive Behaviors, 11, 294–301.
65.Hyman, S. E., & Malenka, R. C. (2001). Addiction and the brain: The neurobiology of
compulsion and its persistence. Nature Reviews Neuroscience, 2, 695–703.
66.McLellan, A. T., Lewis, D. C., O’Brien, C. P., & Kleber, H. D. (2000). Drug
dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes
evaluation. Journal of the American Medical Association, 284, 1689–1695.
67.Nicholls, L., Bragaw, L., & Ruetsch, C. (2010). Opioid dependence treatment and
guidelines. Journal of Managed Care Pharmacy, 16(1), 14-21.
68.Courtwright, D. (1982). Dark paradise: Opiate addiction in America before 1940.
Cambridge, MA: Harvard University Press.
69.Dole, V.P., Robinson, J. W., Orraca, J., Towns, E., Searcy, P., & Caine, E. (1969).
Methadone treatment of randomly selected criminal addicts. New England Journal of
Medicine, 280, 1372–1375.
70. Massing, M. (2000). The fix. Univ of California Press.
71.Hedrich, D., Alves, P., Farrell, M., Stover, H., Moller, L., & Mayet, S. (2012). The
effectiveness of opioid maintenance treatment in prison settings: A systematic review.
Addiction, 107, 501–517.
15. www.PSYCHOconf.ir15
72.Ward, J., W. Hall and R.P. Mattick. (1999) Role of maintenance treatment in opioid
dependence. Lancet, 353, 221–226.
73.Kinlock, T. W., Gordon, M. S., Schwartz, R. P., Fitzgerald, T. T., & O’Grady, K. E.
(2009). Randomized clinical trial of methadone maintenance for prisoners: Results at
twelve months' post-release. Journal of Substance Abuse Treatment, 37, 277–285.
74.Gordon, M. S., Kinlock, T. W., Schwartz, R. P., & O’Grady, K. E. (2008). A
randomized clinical trial of methadone maintenance for prisoners: Findings at 6 months'
post-release. Addiction, 103, 1333–1342.
75.Miller, W. R. & Hester, R. K. (1986). The effectiveness of alcoholism treatment
methods: what research reveals. In: Miller, W. R. & Heather, N., eds. Treating Addictive
Behaviors: Process of Change, pp. 112–134. New York: Plenum Press.
76.Institute of Medicine (1998) Bridging the Gap Between Practice and Research:
Forging Partnerships with Community-Based Drug and Alcohol Treatment. Washington,
DC: National Academy Press.
77.Unt, W. A., Barnett, L. W. & Branch, L. G. (1971) Relapse rates in addiction programs.
Journal of Clinical Psychology, 27, 455– 456.
78.Hubbard, R. L., Marsden, M. E., Rachal, J. V., Harwood, H. J., Cavanaugh, E. R. &
Ginzburg, H. M. (1989) Drug Abuse Treatment: A National Study of Effectiveness. Chapel
Hill, NC: University of North Carolina Press.
79.Hser, Y., Anglin, M. D., Grella, C., Longshore, D. & Prendergast, M. L. (1997) Drug
treatment careers: a conceptual framework and existing research findings. Journal of
Substance Abuse Treatment, 14, 543–558.
80.Hser, Y., Anglin, M. D., Grella, C., Longshore, D. & Prendergast, M. L. (1997) Drug
treatment careers: a conceptual framework and existing research findings. Journal of
Substance Abuse Treatment, 14, 543–558.
81.McKay, J. R., Lynch, K. G., Shepard, D. S., Ratichek, S., Morrison, R., Koppenhaver,
J. & Pettinati, H. M. (2004) The effectiveness of telephone-based continuing care in the
clinical management of alcohol and cocaine use disorders: 12 month outcomes. Journal of
Consulting and Clinical Psychology. 72, 969– 979.
82.Ind B, Chen S,Weatherburn D, Mattick R (2005).The effectiveness of methadone
maintenance treatment in controlling crime. An Australian aggregate-level analysis.
Journal of Criminology 45, 201–211.
83.Hser YI, Saxon AJ, Huang D, et al (2013) Treatment retention among patients
randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Addiction, 109, 79–87.
84.ll J, Trinh L, Butler B, Randall D, Rubin G (2009a). Comparing retention in treatment
and mortality in people after initial entry to methadone and buprenorphine treatment.
Addiction, 104, 1193–1200.
85.Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P (2009b). Comparing overdose
mortality associated with methadone and buprenorphine treatment. Drug and Alcohol
Dependence 104, 73–77.
16. www.PSYCHOconf.ir16
86.Mitchell T B, White J M, Somogyi A A, & Bochner F, (2004) Slow-release oral
morphine versus methadone: a crossover comparison of patient outcomes and acceptability
as maintenance pharmacotherapies for opioid dependence. Addiction, 99(8), 940-945.
87.Eder H, Jagsch R, Kraigher D, et al (2005) Comparative study of the effectiveness of
slow-release morphine and methadone for opioid maintenance therapy. Addiction, 100,
1101–9.